MARKET

MESO

MESO

Mesoblast
NASDAQ
14.30
-0.03
-0.21%
Opening 11:04 07/07 EDT
OPEN
14.40
PREV CLOSE
14.33
HIGH
14.50
LOW
14.20
VOLUME
119.97K
TURNOVER
--
52 WEEK HIGH
21.50
52 WEEK LOW
10.32
MARKET CAP
1.85B
P/E (TTM)
-19.4162
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MESO last week (0629-0703)?
Weekly Report · 1d ago
Largest borrow rate increases among liquid names
TipRanks · 5d ago
BRIEF-Mesoblast Requests Modular Review Of BLA For Rexlemestrocel-L In End-Stage Heart Failure With LVAD
Reuters · 6d ago
Mesoblast wins FDA BLA filing number for rexlemestrocel-L, seeks modular review in LVAD patients
PUBT · 6d ago
Mesoblast receives BLA filing number from FDA for rexlemestrocel-L review
TipRanks · 6d ago
MESOBLAST RECEIVES BLA FILING NUMBER AND REQUESTS MODULAR REVIEW FOR REXLEMESTROCEL-L IN PATIENTS WITH END-STAGE HEART FAILURE AND LVADS
Reuters · 6d ago
MESOBLAST - REXLEMESTROCEL-L RECEIVES ORPHAN DRUG AND RMAT DESIGNATIONS
Reuters · 6d ago
Weekly Report: what happened at MESO last week (0622-0626)?
Weekly Report · 06/29 10:21
More
About MESO
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.